Tag:
Medivir
Latest Headlines
Latest Headlines
J&J and Bristol-Myers ally on another potential hep C blockbuster
The two research powerhouses will conduct a drug-drug interaction study.
Medivir deals generics biz amid HepC drug trials
Eyeing the prospects of its experimental hepatitis C drug, Swedish biotech Medivir ( $MVIR ) has sold off the generics unit of its subsidiary BioPhausia to Bluefish Pharmaceuticals. Medivir scooped up
J&J's success with Hep C partners might hit a snag
Johnson & Johnson ( $JNJ ) is one of the best in the business at tapping outside developers for new drugs, but the Big Pharma's success on this front in the hepatitis C arena appears have brought
Medivir ponders layoffs
Sweden's Medivir says it has alerted employees that it will start cutting costs and raised the possibility of layoffs. "We have a strong pipeline of partnered projects with Tibotec which have
